Wegovy Side Effects: Rare but Serious Adverse Events You Need to Know

What the FDA Black-Box Warning on Wegovy Actually Says

The FDA black-box warning for Wegovy centers on thyroid C-cell tumors. This is the most prominent safety signal on the label, and it stems from rodent carcinogenicity studies showing dose-dependent increases in thyroid C-cell adenomas and carcinomas in rats and mice at clinically relevant exposures.

The Wegovy prescribing information states directly: "Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." [1]

Who Is Contraindicated

Wegovy is contraindicated in patients with a personal or family history of MTC, and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Both conditions dramatically raise the baseline risk that any GLP-1 receptor agonist-induced C-cell stimulation could produce malignant transformation.

What the Human Data Show So Far

The STEP clinical trial program (STEP-1 through STEP-5) enrolled roughly 4,500 participants on semaglutide 2.4 mg and did not detect a statistically significant difference in thyroid neoplasm rates between drug and placebo arms. [2] Calcitonin levels, a surrogate marker for C-cell activity, rose modestly but remained within normal reference ranges in the majority of participants.

A 2023 pharmacoepidemiologic analysis published in JAMA Internal Medicine reported that GLP-1 receptor agonist use was associated with a roughly 50 to 75% higher relative risk of thyroid cancer compared with non-GLP-1 diabetes medications, though absolute rates remained very low and confounding could not be excluded. [3] Patients should receive counseling about symptoms of thyroid tumors: a neck mass, dysphagia, dyspnea, or persistent hoarseness. Serum calcitonin monitoring is not routinely required but may be considered in high-risk individuals.

Pancreatitis: When to Stop Wegovy Immediately

Acute pancreatitis has been reported in patients receiving semaglutide across both the obesity and diabetes indications. GLP-1 receptor agonists as a class carry this signal, and the Wegovy label explicitly instructs prescribers to discontinue the drug if pancreatitis is confirmed. [1]

Incidence Data from STEP Trials

In the pooled STEP-1, STEP-2, and STEP-3 trials (combined N approximately 3,200), pancreatitis was reported in 0.2% of semaglutide-treated patients versus 0.1% in placebo groups. [2] These numbers sound small, but the condition is potentially life-threatening, with a case fatality rate for acute severe pancreatitis approaching 20 to 30% in hospitalized cohorts. [4]

Clinical Warning Signs

Patients should report severe, persistent abdominal pain that radiates to the back, nausea that is qualitatively different from their usual GLP-1 GI side effects, and elevated serum lipase or amylase. A baseline lipase is not mandated by the label but is reasonable for patients with prior pancreatitis history or hypertriglyceridemia above 500 mg/dL.

The HealthRX clinical team uses a three-question screen at every Wegovy follow-up appointment:

1. Is the abdominal pain new, central, and radiating to the back?
2. Has it lasted more than six hours without improvement?
3. Does it differ from your usual nausea or bloating?

Any "yes" triggers a same-day lipase order and suspension of the next Wegovy dose pending results.

Gallbladder Disease: A More Common "Rare" Event

Gallbladder disease is the rare-but-serious adverse event with the highest actual incidence in the STEP program. Rapid weight loss of any cause accelerates cholesterol supersaturation in bile, and GLP-1 receptor agonists may further slow gallbladder emptying via reduced vagal tone.

STEP-1 Cholelithiasis Data

In STEP-1 (N=1,961), cholelithiasis occurred in 1.6% of semaglutide 2.4 mg patients versus 0.7% in the placebo group over 68 weeks. Cholecystitis occurred in 0.8% versus 0.4%, and biliary colic led to cholecystectomy in a subset of those cases. [2]

Risk Factors That Amplify Gallbladder Risk

Patients with a prior history of gallstones, obesity, female sex, rapid weight loss greater than 1.5 kg per week, or current statin use carry elevated baseline risk. The American Association for the Study of Liver Diseases notes that ursodiol (ursodeoxycholic acid) 300 to 600 mg daily may reduce gallstone formation during rapid weight loss programs, though no specific trial has tested it in conjunction with semaglutide. [5]

Symptoms to report: right-upper-quadrant pain, fever with chills (suggesting cholangitis or cholecystitis), and jaundice. Right-upper-quadrant ultrasound is appropriate if any of these develop.

Acute Kidney Injury: The Dehydration Cascade

Wegovy itself is not directly nephrotoxic, but the GI adverse events it produces, specifically nausea, vomiting, and diarrhea, can cause significant volume depletion. That volume depletion, in a patient already taking NSAIDs, ACE inhibitors, ARBs, or diuretics, can precipitate acute kidney injury.

What the FDA Label States

The FDA prescribing information for Wegovy warns: "There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events were reported in patients without known underlying renal disease." [1]

FAERS Signal

The FDA Adverse Event Reporting System (FAERS) database includes hundreds of renal adverse event reports filed against semaglutide (all formulations) through Q3 2024. Many involve patients who experienced prolonged vomiting, reduced oral intake, and then presented to emergency departments with serum creatinine elevations two to five times baseline. [6]

Practical Monitoring Approach

Patients should be advised to maintain hydration aggressively during the dose-escalation phase (weeks 1 to 16 on the standard Wegovy titration schedule). Patients on dual renin-angiotensin blockade or loop diuretics warrant baseline and four-week renal panels. Temporary dose reduction or pause is reasonable for any patient experiencing more than 48 hours of significant vomiting or diarrhea.

Heart Rate Elevation and Cardiovascular Considerations

A mean increase in resting heart rate of 1 to 4 beats per minute was observed consistently across the STEP trial program. [2] For most patients, this is clinically inconsequential. For patients with pre-existing atrial fibrillation, sinus tachycardia, or heart failure with preserved ejection fraction, even modest heart rate elevation can worsen symptoms or precipitate arrhythmia.

SELECT Trial Context

The SELECT trial (N=17,604), which evaluated semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity, showed a 20% relative risk reduction in major adverse cardiovascular events (MACE) compared with placebo over a mean follow-up of 39.8 months. [7] This cardiovascular benefit is large and real. The heart rate signal does not negate it. But patients with symptomatic arrhythmias should have baseline and follow-up ECGs if their cardiologist recommends them.

Caution in Heart Failure

The FDA label notes that the cardiovascular safety of Wegovy in patients with heart failure with reduced ejection fraction (HFrEF, LVEF <40%) has not been established in dedicated trials. STEP-HFpEF (N=529) showed benefit in heart failure with preserved ejection fraction, but the HFrEF population was largely excluded. [8]

Suicidality and Mood Changes: The Current Evidence

In 2023, the FDA and the European Medicines Agency (EMA) both launched reviews of GLP-1 receptor agonists following post-market reports of suicidal ideation and self-harm. The FDA updated prescribing information for Wegovy and other GLP-1 agents to include language advising monitoring for depression and suicidal behavior. [9]

What the EMA Review Found

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) completed its review in April 2024 and concluded that the available evidence does not support a causal relationship between GLP-1 receptor agonist use and suicidality or self-harm. [10] The PRAC noted that obesity itself is associated with higher rates of depression and suicidal ideation, creating a major confounding challenge in observational data.

STEP Trial Psychiatric Data

Across the STEP trials, the incidence of depression and suicidal ideation was low and not statistically different between semaglutide and placebo arms. The Columbia Suicide Severity Rating Scale (C-SSRS) was used as a prospective instrument in STEP-1 and STEP-5, and no signal emerged. [2]

The FDA language in the current label advises prescribers to "monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior." Patients with a history of major depressive disorder or prior suicide attempts should be counseled about this monitoring requirement before starting Wegovy.

Hypoglycemia in Non-Diabetic Patients

Semaglutide 2.4 mg rarely causes hypoglycemia in patients without diabetes. The glucose-lowering effect is glucose-dependent, meaning GLP-1 receptor stimulation drops off at lower glucose concentrations. In STEP-1, which enrolled adults without type 2 diabetes, symptomatic hypoglycemia occurred in fewer than 0.5% of participants on semaglutide 2.4 mg. [2]

Higher Risk Scenarios

The risk increases substantially when Wegovy is co-administered with insulin or sulfonylureas, particularly in patients who have concurrent type 2 diabetes. The FDA label specifically flags this combination as requiring dose adjustment of the concomitant insulin secretagogue or insulin itself to reduce hypoglycemia risk. [1] Patients using continuous glucose monitors should watch for glucose readings below 70 mg/dL with symptoms.

Hypersensitivity and Injection-Site Reactions

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported post-marketing with semaglutide. These are rare, with no precise incidence denominator available from controlled trials, but they require immediate discontinuation and emergency management. [1]

Injection-site reactions such as erythema, nodularity, and pruritus occurred in approximately 1 to 2% of STEP participants and were generally mild and self-limiting. Rotating injection sites across the abdomen, thigh, and upper arm reduces nodularity. If swelling, urticaria, or respiratory symptoms follow an injection, the patient should not receive the next dose and should contact their provider the same day.

Diabetic Retinopathy Complications

In the semaglutide diabetes trials, specifically SUSTAIN-6 (N=3,297, oral and injectable semaglutide at diabetes doses), diabetic retinopathy complications occurred in 3.0% of semaglutide patients versus 1.8% of placebo patients (hazard ratio 1.76, 95% CI 1.11 to 2.78). [11] This signal has not been replicated in the obesity-dose STEP trials where background retinopathy prevalence was lower, but it warrants attention.

Who Needs Ophthalmologic Monitoring

Patients with pre-existing diabetic retinopathy who are starting Wegovy should have a dilated eye exam documented within the prior 12 months. Rapid glucose lowering in poorly controlled diabetes can transiently worsen retinopathy. An HbA1c drop of more than 2 percentage points within the first three months is associated with this risk. [11] Ophthalmology referral is appropriate for any patient who reports new floaters, vision changes, or photopsia after starting semaglutide.

Drug Interactions That Amplify Serious Risk

Wegovy slows gastric emptying, which alters the absorption kinetics of orally administered medications. This is particularly relevant for drugs with narrow therapeutic windows.

Oral contraceptives containing estradiol may show reduced peak concentrations when taken within the first two hours of a semaglutide injection. The Wegovy label recommends taking oral contraceptives at least one hour before or at least four hours after the Wegovy injection during dose escalation. [1] Levothyroxine absorption may similarly be affected; TSH should be rechecked six to eight weeks after starting or adjusting Wegovy in patients on thyroid replacement therapy.

Warfarin INR can fluctuate significantly. Patients on warfarin should have INR checked within two weeks of each Wegovy dose increase.

Post-Market Surveillance: FAERS and Real-World Data Through 2024

The FDA Adverse Event Reporting System catalogues voluntary reports and does not establish causation. Through December 2024, semaglutide (all indications combined) ranked among the top 20 drugs by serious adverse event report volume in FAERS, driven primarily by gastrointestinal events, pulmonary aspiration during anesthesia, and psychiatric events. [6]

Pulmonary Aspiration During Anesthesia

A specific post-market signal that gained prominence in 2023 and 2024 involves aspiration of retained gastric contents during general anesthesia or deep sedation. The American Society of Anesthesiologists (ASA) issued guidance in 2023 recommending that patients on weekly GLP-1 receptor agonists hold their dose for one full week before elective procedures requiring anesthesia, regardless of fasting status. [12]

This recommendation emerged from case reports of patients who had fasted for 12 or more hours but still had significant gastric contents on laryngoscopy, attributed to semaglutide-induced gastroparesis-like delayed gastric emptying. Any planned surgery should trigger a conversation between the patient, their Wegovy prescriber, and the anesthesia team at least two weeks before the procedure date.

How to Report a Serious Adverse Event

Patients and clinicians can report serious adverse events directly to FDA MedWatch at fda.gov/safety/medwatch. Reports contributed to FAERS help the FDA identify new signals and, when the data accumulate, trigger label updates. The SUSTAIN-6 retinopathy signal, the anesthesia-aspiration guidance, and the suicidality monitoring language all originated from post-market surveillance, not pre-approval trials.